Related Experiment Video

Updated: Jul 16, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

KRASG12C/mTORC1 inhibition: a powerful duo in NSCLC therapeutics

Antonios N Gargalionis1, Kostas A Papavassiliou2, Athanasios G Papavassiliou3

  • 1Laboratory of Clinical Biochemistry, Medical School, 'Attikon' University General Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Trends in Pharmacological Sciences
|April 15, 2025
PubMed

Insights

This study introduces a dual-targeting treatment for non-small-cell lung cancer (NSCLC) by inhibiting both active-state KRAS G12C and mTORC1. This combination therapy shows promise in overcoming drug resistance in NSCLC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Non-small-cell lung cancer (NSCLC) frequently harbors the KRAS G12C mutation.
  • Drug resistance remains a significant challenge in NSCLC treatment.
  • Targeting specific mutated proteins like KRAS G12C is a key strategy in precision oncology.

Purpose of the Study:

  • To design a novel combination therapy for NSCLC targeting the active-state KRAS G12C mutation.
  • To investigate the efficacy of dual inhibition of KRAS G12C and mammalian target of rapamycin complex 1 (mTORC1).
  • To explore a potential strategy for overcoming drug resistance in KRAS G12C-mutant NSCLC.

Main Methods:

  • Utilized a combinational treatment approach.
  • Focused on targeting the active-state KRAS G12C-mutant variant.
  • Incorporated selective inhibition of mTORC1.

Main Results:

  • Designed a treatment strategy based on dual targeting.
  • Demonstrated potential for overcoming drug resistance.
  • Highlighted the significance of targeting KRAS G12C (ON) and mTORC1.

Conclusions:

  • Dual targeting of active-state KRAS G12C and mTORC1 offers a new therapeutic strategy for NSCLC.
  • This approach may provide a means to overcome resistance to existing therapies.
  • The findings suggest a promising avenue for improving outcomes in NSCLC patients with KRAS G12C mutations.
Keywords:
ERKKRAS(G12C)mTORC1non-small-cell lung cancer

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...